Wearlink Reels In $14 Million

<p><strong>SAN FRANCISCO<&sol;strong> &&num;8212&semi;  <a class&equals;"ww&lowbar;lnktrkr" href&equals;"https&colon;&sol;&sol;wearlinq&period;com&sol;" target&equals;"&lowbar;blank" rel&equals;"nofollow noopener">Wearlinq<&sol;a>&comma; a provider of wearable health monitoring and diagnosis solutions&comma; has announced &dollar;14 million in Series A funding led by AIX Ventures&comma; along with SpringTide&comma; Berkeley Catalyst Fund&comma; Lightscape Partners&comma; Amino Capital&comma; and others&period; The company is already helping thousands of patients monitor and treat heart disease&comma; the leading cause of death in the United States&period; Alongside the equity round&comma; the company raised &dollar;5 million in venture debt to support its growth&period;<&sol;p>&NewLine;<p>Heart disease is the <a class&equals;"ww&lowbar;lnktrkr" href&equals;"https&colon;&sol;&sol;www&period;cdc&period;gov&sol;heart-disease&sol;data-research&sol;facts-stats&sol;index&period;html&num;&colon;~&colon;text&equals;Heart&percnt;20disease&percnt;20is&percnt;20the&percnt;20leading&comma;&percnt;20lost&percnt;20productivity&percnt;20due&percnt;20to&percnt;20death&period;" target&equals;"&lowbar;blank" rel&equals;"nofollow noopener">leading cause of death<&sol;a> in the U&period;S&period;&comma; claiming 1 in 3 lives&period; Despite the significant human and financial costs&comma; cardiologists still lack a high-quality method for wirelessly monitoring hearts at home or in the hospital&period; At home&comma; most devices track heart rate rather than the electrical rhythm&period; Heart rate alone can’t catch many arrhythmias or the subtle changes that signal rising risk&period; In hospitals&comma; wired telemetry is bulky and brief&comma; and single-lead patches often miss intermittent events&period; The result is a system where patients take devices off&comma; doctors order repeat tests&comma; and heart disease continues to claim millions more lives&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;WearLinq provides a leap forward&comma; bringing multi-lead&comma; high-fidelity arrhythmia data and near real-time patient data outside of the hospital and clinic&period; This is the kind of technology that can reshape how we detect arrhythmias and deliver personalized care to patients in the comfort of their own home&comma;” said Albert Rogers&comma; electrophysiologist at Stanford &amp&semi; Wearlinq co-founder&period;<&sol;p>&NewLine;<p>To solve this&comma; Wearlinq’s eWave is the first continuous&comma; multi-lead &lpar;6-lead&rpar; ECG in a small&comma; wireless form factor that patients will actually wear&period; It’s the only continuous cardiac monitor that pairs with the patient’s personal phone&comma; runs for 5&plus; days between charges&comma; and delivers near-real-time data and reports to clinicians&period; Today&comma; it’s used to detect arrhythmias&period; Over time&comma; the platform will scale to other clinical indications&period; Wearlinq’s eWave is FDA 510&lpar;k&rpar;-cleared&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Even a 10&percnt; reduction in early heart disease death in the U&period;S&period; equates to over 100&comma;000 lives saved&comma;” explained Konrad Morzkowski&comma; co-founder and CEO of WearLinq&period; &OpenCurlyDoubleQuote;There is no bigger mission for us&comma; and this new funding gives us the ability to scale eWave nationally&period;”<&sol;p>&NewLine;<p>The company’s complete list of investors includes AIX Ventures&comma; SpringTide&comma; Berkeley Catalyst Fund&comma; Lightscape Partners&comma; Solasta&comma; Alumni Ventures&comma; Amino Capital&comma; Angelschool&comma; LDV Partners&comma; Maliam&comma; XB Ventures&comma; Celtic House Asia Partners Health&comma; Device of Tomorrow Capital&comma; NYX Ventures Partners&comma; and SmartLink Partners&period;<&sol;p>&NewLine;